Ashish M. Kamat

30.7k total citations · 10 hit papers
540 papers, 18.8k citations indexed

About

Ashish M. Kamat is a scholar working on Surgery, Urology and Oncology. According to data from OpenAlex, Ashish M. Kamat has authored 540 papers receiving a total of 18.8k indexed citations (citations by other indexed papers that have themselves been cited), including 458 papers in Surgery, 120 papers in Urology and 118 papers in Oncology. Recurrent topics in Ashish M. Kamat's work include Bladder and Urothelial Cancer Treatments (424 papers), Urinary and Genital Oncology Studies (288 papers) and Urological Disorders and Treatments (107 papers). Ashish M. Kamat is often cited by papers focused on Bladder and Urothelial Cancer Treatments (424 papers), Urinary and Genital Oncology Studies (288 papers) and Urological Disorders and Treatments (107 papers). Ashish M. Kamat collaborates with scholars based in United States, Canada and Italy. Ashish M. Kamat's co-authors include Colin P. Dinney, Wassim Kassouf, Yair Lotan, H. Barton Grossman, Shahrokh F. Shariat, Arlene O. Siefker‐Radtke, Surena F. Matin, Donald L. Lamm, Seth P. Lerner and Charles C. Guo and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Ashish M. Kamat

513 papers receiving 18.5k citations

Hit Papers

Bladder cancer 2009 2026 2014 2020 2016 2009 2017 2018 2010 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Bladder cancer
    2016 1.0k citations Ashish M. Kamat, Seth P. Lerner et al. profile →
  2. Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration
    2009 780 citations Shahrokh F. Shariat, Ashish M. Kamat et al. profile →
  3. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
    2017 613 citations Bernard H. Bochner, Ashish M. Kamat et al. The Journal of Urology profile →
  4. Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018
    2018 533 citations Marcus Cumberbatch, Ibrahim Jubber et al. European Urology profile →
  5. Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
    2010 358 citations Bradley Curtis Carthon, Jedd D. Wolchok et al. Clinical Cancer Research profile →
  6. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
    2021 329 citations Arjun Vasant Balar, Ashish M. Kamat et al. The Lancet Oncology profile →
  7. Current best practice for bladder cancer: a narrative review of diagnostics and treatments
    2022 233 citations Éva Compérat, Ashish M. Kamat et al. profile →
  8. Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors
    2023 222 citations Ibrahim Jubber, Peter C. Black et al. European Urology profile →
  9. Repeat Transurethral Resection in Non–muscle-invasive Bladder Cancer: A Systematic Review
    2018 218 citations Marcus Cumberbatch, James W.F. Catto et al. European Urology profile →
  10. Recurrence mechanisms of non-muscle-invasive bladder cancer — a clinical perspective
    2022 102 citations Ashish M. Kamat, Peter C. Black et al. Nature Reviews Urology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ashish M. Kamat United States 69 13.3k 4.6k 4.1k 3.8k 3.2k 540 18.8k
Colin P. Dinney United States 79 12.9k 1.0× 5.8k 1.3× 7.7k 1.9× 3.2k 0.8× 4.6k 1.4× 492 21.8k
Seth P. Lerner United States 66 12.6k 0.9× 3.6k 0.8× 4.0k 1.0× 3.8k 1.0× 3.0k 0.9× 375 16.4k
Maximilian Burger Germany 47 12.4k 0.9× 2.8k 0.6× 3.1k 0.7× 3.7k 1.0× 2.9k 0.9× 258 15.4k
Bernard H. Bochner United States 58 14.4k 1.1× 3.4k 0.7× 2.5k 0.6× 6.0k 1.6× 3.1k 1.0× 338 17.6k
Yves Fradet Canada 65 8.7k 0.7× 4.8k 1.0× 3.4k 0.8× 2.1k 0.6× 5.2k 1.6× 376 16.1k
Éva Compérat France 59 15.0k 1.1× 3.9k 0.9× 4.2k 1.0× 5.0k 1.3× 6.0k 1.9× 367 20.8k
Wassim Kassouf Canada 57 10.2k 0.8× 2.7k 0.6× 2.6k 0.6× 3.3k 0.9× 3.4k 1.1× 380 13.6k
Guido Dalbagni United States 63 12.7k 1.0× 3.1k 0.7× 2.8k 0.7× 4.8k 1.3× 2.6k 0.8× 276 15.3k
Sam S. Chang United States 45 4.9k 0.4× 2.4k 0.5× 2.2k 0.5× 1.9k 0.5× 3.1k 1.0× 209 9.9k
Guru Sonpavde United States 53 6.5k 0.5× 6.9k 1.5× 3.3k 0.8× 827 0.2× 5.1k 1.6× 628 15.1k

Countries citing papers authored by Ashish M. Kamat

Since Specialization
Citations

This map shows the geographic impact of Ashish M. Kamat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ashish M. Kamat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ashish M. Kamat more than expected).

Fields of papers citing papers by Ashish M. Kamat

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ashish M. Kamat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ashish M. Kamat. The network helps show where Ashish M. Kamat may publish in the future.

Co-authorship network of co-authors of Ashish M. Kamat

This figure shows the co-authorship network connecting the top 25 collaborators of Ashish M. Kamat. A scholar is included among the top collaborators of Ashish M. Kamat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ashish M. Kamat. Ashish M. Kamat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pavlick, Dean C., S. Lindsey Davis, Christopher H. Lieu, et al.. (2025). Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study. ESMO Open. 10(6). 105312–105312.
2.
Li, Roger, Ashish M. Kamat, Petros Grivas, et al.. (2025). Primary sarcomas of the bladder and prostate: A genomic landscape study. Pathology - Research and Practice. 267. 155840–155840.
3.
Li, Roger, James W.F. Catto, Siamak Daneshmand, et al.. (2024). FGFR Inhibition in Urothelial Carcinoma. European Urology. 87(2). 110–122. 12 indexed citations
4.
Gupta, Shilpa, Philippe E. Spiess, Ashish M. Kamat, et al.. (2024). The spectrum of cutaneous toxicities related to novel genitourinary cancer therapies. Critical Reviews in Oncology/Hematology. 200. 104420–104420. 3 indexed citations
5.
Briganti, Alberto, Bradley C. Leibovich, Seth P. Lerner, et al.. (2023). Contemporary Role of Lymph Node Dissection in Genitourinary Cancers: Where Are We in 2023?. European Urology Oncology. 7(3). 412–420. 3 indexed citations
6.
Kulkarni, Girish S., Kyle A. Richards, Peter C. Black, et al.. (2023). MP63-01 AN INTERIM ANALYSIS OF A PHASE II CLINICAL STUDY OF INTRAVESICAL PHOTO DYNAMIC THERAPY IN PATIENTS WITH BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CARCINOMA IN-SITU (CIS). The Journal of Urology. 209(Supplement 4). 3 indexed citations
7.
Balar, Arjun Vasant, Ashish M. Kamat, Girish S. Kulkarni, et al.. (2021). Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. The Lancet Oncology. 22(7). 919–930. 329 indexed citations breakdown →
8.
Cumberbatch, Marcus, Ashish M. Kamat, John McGrath, et al.. (2020). Reporting radical cystectomy outcomes following implementation of Enhanced Recovery after Surgery (ERAS) protocols: A systematic review and individual patient data meta-analysis. European Urology Open Science. 19. e2280–e2280. 15 indexed citations
9.
10.
Lotan, Yair, Trinity J. Bivalacqua, Tracy M. Downs, et al.. (2019). Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA — update 2018. Nature Reviews Urology. 16(6). 377–386. 59 indexed citations
11.
Moschini, Marco, Shahrokh F. Shariat, Peter C. Black, et al.. (2019). Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails. European Urology. 77(1). 1–2. 4 indexed citations
12.
Smith, Angela B., Siamak Daneshmand, Sanjay Patel, et al.. (2018). Patient‐reported outcomes of blue‐light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study. British Journal of Urology. 123(1). 35–41. 9 indexed citations
13.
Jinesh, Goodwin G. & Ashish M. Kamat. (2017). The Blebbishield Emergency Program Overrides Chromosomal Instability and Phagocytosis Checkpoints in Cancer Stem Cells. Cancer Research. 77(22). 6144–6156. 15 indexed citations
14.
Williams, Stephen B., Yuanqing Ye, Maosheng Huang, et al.. (2015). Mitochondrial DNA Content as Risk Factor for Bladder Cancer and Its Association with Mitochondrial DNA Polymorphisms. Cancer Prevention Research. 8(7). 607–613. 17 indexed citations
15.
Kamat, Ashish M., Wei Wei, Dan Leibovici, et al.. (2014). Anterior Fascial Fixation Does Not Reduce the Parastomal Hernia Rate After Radical Cystectomy and Ileal Conduit. Urology. 83(6). 1427–1432. 15 indexed citations
16.
Gu, Jian, Meng Chen, Sanjay Shete, et al.. (2011). A Genome-Wide Association Study Identifies a Locus on Chromosome 14q21 as a Predictor of Leukocyte Telomere Length and as a Marker of Susceptibility for Bladder Cancer. Cancer Prevention Research. 4(4). 514–521. 53 indexed citations
17.
Carthon, Bradley Curtis, Jedd D. Wolchok, Jianda Yuan, et al.. (2010). Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial. Clinical Cancer Research. 16(10). 2861–2871. 358 indexed citations breakdown →
18.
Inamoto, Teruo, Sabitha Papineni, Sudhakar Chintharlapalli, et al.. (2008). 1,1-Bis(3′-indolyl)-1-( p -chlorophenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growth. Molecular Cancer Therapeutics. 7(12). 3825–3833. 87 indexed citations
19.
Liakou, Chrysoula I., Ashish M. Kamat, Derek Ng Tang, et al.. (2008). CTLA-4 blockade increases IFNγ-producing CD4 + ICOS hi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proceedings of the National Academy of Sciences. 105(39). 14987–14992. 428 indexed citations
20.
Kamat, Ashish M., Samuel Huang, Carlos E. Bermejo, et al.. (2003). Total Pelvic Exenteration: Effective Palliation of Perineal Pain in Patients With Locally Recurrent Prostate Cancer. The Journal of Urology. 170(5). 1868–1871. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Colin P. Dinney Breakdown of academic impact, for papers by Seth P. Lerner Breakdown of academic impact, for papers by Maximilian Burger Breakdown of academic impact, for papers by Bernard H. Bochner Breakdown of academic impact, for papers by Yves Fradet Breakdown of academic impact, for papers by Éva Compérat Breakdown of academic impact, for papers by Wassim Kassouf Breakdown of academic impact, for papers by Guido Dalbagni Breakdown of academic impact, for papers by Sam S. Chang Breakdown of academic impact, for papers by Guru Sonpavde
Rankless by CCL
2026